3O Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with fulvestrant in oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutant advanced breast cancer
Titel:
3O Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with fulvestrant in oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutant advanced breast cancer
Auteur:
Jacot, W. Savage, H.M. Dent, S. Cortés, J. Im, Y-H. Dieras, V.C. Harbeck, N. Krop, I.E. Chen, J. Sokol, E. Schimmoller, F. Hsu, J. De Laurentiis, M. Wilson, T.R.